|
C12ORF43 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66160418757499E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.33920052403892E-10 |
| Normal-vs-Stage2 |
1.643720E-03 |
| Normal-vs-Stage3 |
2.60879984281814E-10 |
| Normal-vs-Stage4 |
1.6565637750432E-12 |
| Stage1-vs-Stage2 |
1.764790E-01 |
| Stage1-vs-Stage3 |
1.424410E-01 |
| Stage1-vs-Stage4 |
1.557510E-04 |
| Stage2-vs-Stage3 |
3.886000E-02 |
| Stage2-vs-Stage4 |
1.018140E-03 |
| Stage3-vs-Stage4 |
3.908300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.02549968516996E-10 |
| Normal-vs-AfricanAmerican |
9.75820000359562E-08 |
| Normal-vs-Asian |
5.87399999999461E-05 |
| Caucasian-vs-AfricanAmerican |
2.867600E-01 |
| Caucasian-vs-Asian |
2.248400E-01 |
| AfricanAmerican-vs-Asian |
6.550200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.10165218561542E-13 |
| Normal-vs-Female |
1.29749999633333E-09 |
| Male-vs-Female |
2.909700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.91789958651157E-10 |
| Normal-vs-Age(41-60Yrs) |
2.35110000357253E-08 |
| Normal-vs-Age(61-80Yrs) |
7.72271135929259E-12 |
| Normal-vs-Age(81-100Yrs) |
4.978900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.463200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.239230E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.703000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.505170E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.905000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.765800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.463700E-02 |
| Classical-VS-Follicular |
7.759200E-01 |
| Classical-VS-Other |
1.194570E-01 |
| Classical-VS-Normal |
9.33380039924714E-11 |
| Tall-VS-Follicular |
9.340400E-02 |
| Tall-VS-Other |
7.132400E-01 |
| Tall-VS-Normal |
2.5320000540674E-09 |
| Follicular-VS-Other |
3.176000E-01 |
| Follicular-VS-Normal |
8.41350000002627E-07 |
| Other-VS-Normal |
2.975600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.18930000479057E-08 |
| Normal-vs-N1 |
1.2170264795941E-12 |
| N0-vs-N1 |
1.539810E-03 |
|
|
